Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-4,000
Closed -$251K 5140
2026
Q1
$251K Buy
+4,000
New +$279K ﹤0.01% 4176
2022
Q1
Sell
-26,000
Closed -$3.49M 3115
2021
Q4
$3.49M Buy
26,000
+7,200
+38% +$1.03M 0.01% 1451
2021
Q3
$2.57M Sell
18,800
-8,800
-32% -$1.11M 0.01% 1746
2021
Q2
$2.95M Buy
27,600
+22,000
+393% +$2.11M 0.01% 1562
2021
Q1
$503K Sell
5,600
-64,400
-92% -$6.05M ﹤0.01% 2925
2020
Q4
$6.47M Sell
70,000
-38,400
-35% -$3.43M 0.02% 787
2020
Q3
$11.2M Buy
108,400
+56,400
+108% +$5.89M 0.04% 468
2020
Q2
$5.27M Sell
52,000
-19,200
-27% -$1.72M 0.03% 625
2020
Q1
$4.79M Buy
71,200
+49,600
+230% +$3.09M 0.04% 529
2019
Q4
$1.18M Sell
21,600
-7,200
-25% -$342K ﹤0.01% 2045
2019
Q3
$1.07M Buy
28,800
+16,800
+140% +$653K ﹤0.01% 1931
2019
Q2
$450K Buy
+12,000
New +$377K ﹤0.01% 2582
2018
Q2
Sell
-119,600
Closed -$2.22M 3386
2018
Q1
$2.22M Buy
+119,600
New +$1.77M 0.01% 1450
2017
Q3
Sell
-25,200
Closed -$461K 2825
2017
Q2
$461K Sell
25,200
-21,200
-46% -$392K ﹤0.01% 2398
2017
Q1
$983K Buy
+46,400
New +$906K ﹤0.01% 1947

Other funds holding DXCM

John Overdeck's DXCM Position: Q2 2026 in Review

John Overdeck reduced its DexCom (DXCM) stake by 96% in Q2 2026, selling an estimated $71.2M and leaving 46,697 shares worth $3.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2578.

John Overdeck first reported a position in DXCM in Q2 2013 and has held it in 36 quarters since. The position peaked at $193M in Q4 2021. 966 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • John Overdeck held 46,697 shares of DexCom worth $3.15M as of Q2 2026.
  • John Overdeck sold 1,068,251 DexCom shares in Q2 2026, an estimated $71.2M.
  • DexCom made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2578 holding.
  • John Overdeck first reported a position in DexCom in Q2 2013 and has held it in 36 quarters since.
  • John Overdeck's DexCom position peaked at $193M in Q4 2021.
  • 966 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.